Back to results
US 12,611,405 B2Granted
Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer
AssigneeLDN Pharma Limited
InventorsAngus Dalgleish, Wai Lui
Life of this patent
Estimating the term…
Abstract
The present invention provides an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent wherein the agent is selected from the list consisting of 6-β-naltrexol, naloxone, methyl naltrexone, or pharmaceutically acceptable salts thereof.
Claims18
A packaged preparation comprising:
- (a) a pharmaceutical composition in a solid dosage form comprising from 0.01 mg to up to 40 mg per tablet of an agent that increases the expression of BAD (Bcl2-associated agonist cell death), wherein the agent is 6-β-naltrexol, or pharmaceutically acceptable salts thereof, and
- (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is selected from the group consisting of a class of antimetabolite chemotherapeutic agents and a class of alkylating chemotherapeutic agents
- in the treatment of cancer, wherein the cancer is selected from the group consisting of colon cancer, breast cancer and lung cancer.
Dependencies are inferred from the claim text.